These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34427452)

  • 1. Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in
    Doebele RC; Perez L; Trinh H; Martinec M; Martina R; Riehl T; Krebs MG; Meropol NJ; Wong WB; Crane G
    J Comp Eff Res; 2021 Dec; 10(17):1271-1282. PubMed ID: 34427452
    [No Abstract]   [Full Text] [Related]  

  • 2. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
    Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs MG; Shaw AT; de Braud F; Rolfo C; Ahn MJ; Wolf J; Seto T; Cho BC; Patel MR; Chiu CH; John T; Goto K; Karapetis CS; Arkenau HT; Kim SW; Ohe Y; Li YC; Chae YK; Chung CH; Otterson GA; Murakami H; Lin CC; Tan DSW; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Doebele RC;
    Lancet Oncol; 2020 Feb; 21(2):261-270. PubMed ID: 31838015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of crizotinib versus entrectinib in
    Tremblay G; Groff M; Iadeluca L; Daniele P; Wilner K; Wiltshire R; Bartolome L; Usari T; Cappelleri JC; Camidge DR
    Future Oncol; 2022 Jun; 18(17):2063-2074. PubMed ID: 35232230
    [No Abstract]   [Full Text] [Related]  

  • 4. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic
    Dziadziuszko R; Krebs MG; De Braud F; Siena S; Drilon A; Doebele RC; Patel MR; Cho BC; Liu SV; Ahn MJ; Chiu CH; Farago AF; Lin CC; Karapetis CS; Li YC; Day BM; Chen D; Wilson TR; Barlesi F
    J Clin Oncol; 2021 Apr; 39(11):1253-1263. PubMed ID: 33646820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matching-adjusted indirect comparison: entrectinib versus crizotinib in
    Chu P; Antoniou M; Bhutani MK; Aziez A; Daigl M
    J Comp Eff Res; 2020 Aug; 9(12):861-876. PubMed ID: 32648475
    [No Abstract]   [Full Text] [Related]  

  • 6. Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study.
    Waterhouse D; Iadeluca L; Sura S; Wilner K; Emir B; Krulewicz S; Espirito J; Bartolome L
    Target Oncol; 2022 Jan; 17(1):25-33. PubMed ID: 34964940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Efficacy and Safety of Entrectinib in
    Drilon A; Chiu CH; Fan Y; Cho BC; Lu S; Ahn MJ; Krebs MG; Liu SV; John T; Otterson GA; Tan DSW; Patil T; Dziadziuszko R; Massarelli E; Seto T; Doebele RC; Pitcher B; Kurtsikidze N; Heinzmann S; Siena S
    JTO Clin Res Rep; 2022 Jun; 3(6):100332. PubMed ID: 35663414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
    Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
    Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements.
    Delgado J; Pean E; Melchiorri D; Migali C; Josephson F; Enzmann H; Pignatti F
    ESMO Open; 2021 Apr; 6(2):100087. PubMed ID: 33735800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of crizotinib in patients with
    Nogami N; Nakamura A; Shiraiwa N; Kikkawa H; Emir B; Wiltshire R; Morise M
    Future Oncol; 2023 Dec; 19(37):2453-2463. PubMed ID: 37605861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study).
    Janzic U; Maimon Rabinovich N; Shalata W; Kian W; Szymczak K; Dziadziuszko R; Jakopovic M; Mountzios G; Pluzanski A; Araujo A; Charpidou A; Daher S; Agbarya A
    Curr Oncol; 2024 Jul; 31(8):4369-4381. PubMed ID: 39195309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours.
    Paz-Ares L; Barlesi F; Siena S; Ahn MJ; Drilon A; Conley A; Rolfo C; Wolf J; Seto T; Doebele R; Kapre A; Chen D; McCallum S; Osborne S; Demetri G
    ESMO Open; 2021 Jun; 6(3):100113. PubMed ID: 33930659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
    Drilon A; Siena S; Ou SI; Patel M; Ahn MJ; Lee J; Bauer TM; Farago AF; Wheler JJ; Liu SV; Doebele R; Giannetta L; Cerea G; Marrapese G; Schirru M; Amatu A; Bencardino K; Palmeri L; Sartore-Bianchi A; Vanzulli A; Cresta S; Damian S; Duca M; Ardini E; Li G; Christiansen J; Kowalski K; Johnson AD; Patel R; Luo D; Chow-Maneval E; Hornby Z; Multani PS; Shaw AT; De Braud FG
    Cancer Discov; 2017 Apr; 7(4):400-409. PubMed ID: 28183697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of lung adenocarcinoma with a novel CD74-ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib.
    Hashiguchi MH; Sato T; Watanabe R; Kagyo J; Matsuzaki T; Domoto H; Kato T; Nakahara Y; Yokose T; Hiroshima Y; Shiomi T
    Thorac Cancer; 2021 Sep; 12(18):2504-2507. PubMed ID: 34319660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to Crizotinib After Entrectinib Resistance in
    Vaz VR; Gandhi MM; Ricciuti B; Alessi JV; Elkrief A; Ladanyi M; Vanderbilt C; Pecci F; Aldea M; Barrichello A; Saini A; Sholl L; Sands JM; Awad MM
    JCO Precis Oncol; 2024 Oct; 8():e2400394. PubMed ID: 39374479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer.
    Cho BC; Chiu CH; Massarelli E; Buchschacher GL; Goto K; Overbeck TR; Loong HHF; Chee CE; Garrido P; Dong X; Fan Y; Lu S; Schwemmers S; Bordogna W; Zeuner H; Osborne S; John T
    Lung Cancer; 2024 Feb; 188():107442. PubMed ID: 38171156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer.
    Roth JA; Carlson JJ; Xia F; Williamson T; Sullivan SD
    J Manag Care Spec Pharm; 2020 Aug; 26(8):981-986. PubMed ID: 32329651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
    Desai AV; Robinson GW; Gauvain K; Basu EM; Macy ME; Maese L; Whipple NS; Sabnis AJ; Foster JH; Shusterman S; Yoon J; Weiss BD; Abdelbaki MS; Armstrong AE; Cash T; Pratilas CA; Corradini N; Marshall LV; Farid-Kapadia M; Chohan S; Devlin C; Meneses-Lorente G; Cardenas A; Hutchinson KE; Bergthold G; Caron H; Chow Maneval E; Gajjar A; Fox E
    Neuro Oncol; 2022 Oct; 24(10):1776-1789. PubMed ID: 35395680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entrectinib: A New Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusionpositive, Recurrent or Advanced Solid Tumors.
    Osman HM; Tuncbilek M
    Curr Med Chem; 2022; 29(15):2602-2616. PubMed ID: 34521321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications.
    Krebs MG; Blay JY; Le Tourneau C; Hong D; Veronese L; Antoniou M; Bennett I
    ESMO Open; 2021 Apr; 6(2):100072. PubMed ID: 33676294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.